This article is part of the supplement: Proceedings of the 2011 International Conference on Bioinformatics and Computational Biology (BIOCOMP'11)
Development of a novel DNA sequencing method not only for hepatitis B virus genotyping but also for drug resistant mutation detection
- Equal contributors
1 State Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan 430072, P.R. China
2 Guangzhou Kingmed Center for Clinical Laboratory, Guangzhou 524035, P.R. China
3 Wuhan University of Science and Technology, Wuhan 430081, P.R. China
BMC Medical Genomics 2013, 6(Suppl 1):S15 doi:10.1186/1755-8794-6-S1-S15Published: 23 January 2013
In HBV-infected patients, different genotypes of the hepatitis B virus influence liver disease progression and response to antiviral therapy. Moreover, long-term antiviral therapy will eventually select for drug-resistant mutants. Detection of mutations associated to antiviral therapy and HBV genotyping are essential for monitoring treatment of chronic hepatitis B patients.
In this study, a simple method of partial-S gene sequencing using a common PCR amplification was established for genotyping clinical HBV isolates sensitively, which could detect the drug-resistant mutations successfully at the same time.
The partial S gene sequencing assay developed in this study has potential for application in HBV genotyping and drug resistant mutation detection. It is simpler and more convenient than traditional S gene sequencing, but has nearly the same sensitivity and specificity when compared to S gene sequencing.